14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XOMA vs AGEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Agenus Inc. (AGEN) captures the overall head-to-head institutional edge over XOMA Royalty Corporation (XOMA) on higher Unified Composite conviction (52.7/100 HOLD vs. 55.8/100 HOLD) after splitting the core matrix 3–7 (led by Valuation Multiples, Options & Positioning), while XOMA wins 3–2 across the 6-pillar growth and valuation breakdown. XOMA trades at $40.17 (21.5x Forward P/E, -3.9% operating margin) versus AGEN at $6.34 (3.7x Forward P/E, 38.9% operating margin).
Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. AGEN 52.7/100 HOLD), AGEN captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -3.9% operating margin) and revenue trajectory (+4.1% vs. -22.6% YoY).
Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile AGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs AGEN. Trailing 12-month operating profitability (XOMA -3.9% vs AGEN 38.9%) and valuation multiples (XOMA 21.5x vs AGEN 3.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
AGEN Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $310.8M market capitalization and 38.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XOMA vs AGEN Key Questions & Quantitative Answers
As of Nov 16, 2026, Agenus Inc. (AGEN) captures the overall head-to-head institutional edge over XOMA Royalty Corporation (XOMA) on higher Unified Composite conviction (52.7/100 HOLD vs. 55.8/100 HOLD) after splitting the core matrix 3–7 (led by Valuation Multiples, Options & Positioning), while XOMA wins 3–2 across the 6-pillar growth and valuation breakdown. XOMA trades at $40.17 (21.5x Forward P/E, -3.9% operating margin) versus AGEN at $6.34 (3.7x Forward P/E, 38.9% operating margin). Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. AGEN 52.7/100 HOLD), AGEN captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -3.9% operating margin) and revenue trajectory (+4.1% vs. -22.6% YoY). Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile AGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
XOMA leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with AGEN at +4.1% YoY revenue growth and -99.0% YoY earnings growth on $34M TTM revenue (N/A gross margin, 38.9% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus $34M for AGEN. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AGEN.
AGEN screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas AGEN trades at 3.7x Forward P/E, 29.9x Trailing P/E, 1.44x PEG, and 8.9x EV/Revenue (-103.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus AGEN (-1278.8% ROE) capital efficiency.
In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, AGEN carries 95.2% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.60β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.